Cargando…

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

BACKGROUND: Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications. METHODS: In this obs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bariola, J Ryan, McCreary, Erin K, Wadas, Richard J, Kip, Kevin E, Marroquin, Oscar C, Minnier, Tami, Koscumb, Stephen, Collins, Kevin, Schmidhofer, Mark, Shovel, Judith A, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M, Nace, David A, Huang, David T, Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Seymour, Christopher W, Montgomery, Stephanie K, Angus, Derek C, Snyder, Graham M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241472/ https://www.ncbi.nlm.nih.gov/pubmed/34250192 http://dx.doi.org/10.1093/ofid/ofab254

Ejemplares similares

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization
por: Huang, David T., et al.
Publicado: (2021)

Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days
por: McCreary, Erin K., et al.
Publicado: (2022)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022)

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022)

Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic
por: Bariola, J Ryan, et al.
Publicado: (2021)

A learning health system approach to the COVID‐19 pandemic: System‐wide changes in clinical practice and 30‐day mortality among hospitalized patients
por: McCreary, Erin K., et al.
Publicado: (2022)

The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial
por: McCreary, Erin K., et al.
Publicado: (2022)

470. Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study
por: Haidar, Ghady, et al.
Publicado: (2023)

Immunology of Nonhospital and Intrahospital Infections
por: Zemskov, V. M., et al.
Publicado: (2021)

951. Implementation and Rapid Uptake of an Antimicrobial Stewardship Clinical Decision Support System Across 19 UPMC Hospitals
por: Ryan Bariola, J, et al.
Publicado: (2022)

Impact of Clinical Decision Support System Implementation at a Community Hospital With an Existing Tele-Antimicrobial Stewardship Program
por: Khadem, Tina M, et al.
Publicado: (2022)

2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR) Pseudomonas aeruginosa
por: Shah, Sunish, et al.
Publicado: (2023)

Evaluation of Adrenal Function in Nonhospitalized Patients with Cirrhosis
por: Moini, Maryam, et al.
Publicado: (2017)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Preprocedural SARS-CoV-2 Testing to Sustain Medically Needed Health Care Delivery During the COVID-19 Pandemic: A Prospective Observational Study
por: Haidar, Ghady, et al.
Publicado: (2021)

Colonoscopy quality in community hospitals and nonhospital facilities in Korea
por: Lee, Jae Gon, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?
por: Rezende, Suely M., et al.
Publicado: (2023)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China
por: Ding, Hong, et al.
Publicado: (2020)

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
por: Chhiba, Krishan D., et al.
Publicado: (2020)

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
por: Hammond, Jennifer, et al.
Publicado: (2022)

Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19
por: Fang, Margaret C., et al.
Publicado: (2023)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Use of donor human milk in nonhospitalized infants: An infant growth study
por: Bramer, Solange, et al.
Publicado: (2021)

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
por: Martin, David E., et al.
Publicado: (2023)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

191. Accuracy of Clinical Indications for Use When Ordering Antibiotics for Cystitis in Community Hospitals
por: Khadem, Tina, et al.
Publicado: (2018)

1880. Does the Label Matter: Initial Use of Newly Approved Antimicrobial Agents in Community Hospitals Without Robust Antimicrobial Stewardship Programs
por: Khadem, Tina, et al.
Publicado: (2018)

1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System
por: Bariola, J Ryan, et al.
Publicado: (2019)

1067. Variation of Antimicrobial Stewardship Programs’ Membership and Organization Within a Single Health System
por: Bariola, J Ryan, et al.
Publicado: (2019)

Jardines de interior : crea 40 jardines de interior para tu hogar en cualquier estación del año
por: McCreary, Rosemary
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vc4mamecj5gunrc1knbus0adl9